Our Take
Phylloceuticals has a working pilot and two signed customers, but the real test is whether pharma will swap entrenched mammalian cell infrastructure for an unproven platform, even at 80% cost savings.
Why it matters
The biopharmaceutical industry faces $300 billion in revenue loss over the next four years as blockbuster patents expire. Biosimilar manufacturers need production methods that undercut originator costs without regulatory friction, and Phylloceuticals' approach addresses both.
Do this week
Biosimilar manufacturers: request a technical data package and pilot batch from Phylloceuticals before your next capacity planning cycle, so you can model the cost differential and scaleup timeline against your mammalian cell baseline.
Phylloceuticals built a duckweed-based antibody factory
Phylloceuticals, incorporated in 2024 and operationalized in January 2025, has opened a pilot facility in Rapid City, South Dakota. The company uses Lemna (duckweed) as a living bioreactor to produce monoclonal antibodies instead of the industry-standard Chinese hamster ovary (CHO) cell lines.
In proof-of-concept work, the team produced microgram quantities of pembrolizumab, a PD-1 inhibitor, in 16 weeks at yields of approximately 0.6 grams purified monoclonal antibody per kilogram of fresh weight (company-reported). Line development takes four to six months versus 18+ months for CHO cells. CEO Susan Stipa claims the platform cuts upstream operational costs by 80–90% per gram and one-third the total manufacturing cost (company-reported).
The company has signed its first two customers: one in preclinical joint-disease studies and one in animal health biologics. Stipa says she expects to close an angel round soon, followed immediately by Series A funding.
Biosimilar makers face margin pressure from patent cliffs
Approximately 200 biopharmaceuticals are scheduled to go off patent in the next four years, representing roughly $300 billion in revenue loss (per the article). Manufacturers defending that exposure have traditionally pursued mergers, reformulations, and cost reduction through headcount cuts. Lemna production offers a structural cost advantage instead.
Duckweed doubles in optimal conditions within 36 hours (versus five to seven days in the wild). It requires inexpensive, animal serum-free growth media, has no adventitious viruses, produces a near-zero carbon footprint, and uses about 10% of the water that CHO systems demand. Critically for regulators, Lemna has commercial-scale history in food and pharmaceutical products that cleared Phase II trials, including β-interferon, though not yet in commercial pharmaceutical production.
The Biosecure Act (signed December 2024) and Federal Acquisition Regulations banning commerce with "companies of concern" make onshore, low-cost monoclonal antibody production strategically valuable. A duckweed platform based in rural South Dakota aligns with both the regulatory push for domestic manufacturing and the biosimilar cost model.
Scaleup remains the open question
Phylloceuticals currently produces microgram-to-gram quantities. The next phase is gram-to-kilogram scale, and commercial manufacturing at tons-per-year volume remains unproven. The company acknowledges that extraction from the apoplast (the intercellular spaces where protein accumulates) and scaling to commercial quantities are still being optimized.
The largest barrier is not scientific but cultural. Stipa notes that pharma has multi-billion-dollar investments in stainless steel mammalian cell infrastructure. Switching to a plant-based system requires forward-thinking leadership willing to abandon "how we've always done it." Two early customers suggest such leaders exist, but the path from pilot validation to industry adoption is measured in years, not quarters.